HK1131912A1 - Pharmaceutical compositions and methods useful for modulating angiogenesis - Google Patents

Pharmaceutical compositions and methods useful for modulating angiogenesis

Info

Publication number
HK1131912A1
HK1131912A1 HK09111737.6A HK09111737A HK1131912A1 HK 1131912 A1 HK1131912 A1 HK 1131912A1 HK 09111737 A HK09111737 A HK 09111737A HK 1131912 A1 HK1131912 A1 HK 1131912A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
methods useful
modulating angiogenesis
angiogenesis
mammalian tissue
Prior art date
Application number
HK09111737.6A
Other languages
English (en)
Inventor
Gera Neufeld
Gal Akiri
Zhava Vadasz
Stela Gengrovitch
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Publication of HK1131912A1 publication Critical patent/HK1131912A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK09111737.6A 2000-08-08 2009-12-14 Pharmaceutical compositions and methods useful for modulating angiogenesis HK1131912A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08

Publications (1)

Publication Number Publication Date
HK1131912A1 true HK1131912A1 (en) 2010-02-12

Family

ID=22837793

Family Applications (3)

Application Number Title Priority Date Filing Date
HK12101876.3A HK1161113A1 (en) 2000-08-08 2009-12-14 Pharmaceutical compositions and methods useful for modulating angiogenesis
HK12101889.8A HK1161115A1 (en) 2000-08-08 2009-12-14 Pharmaceutical compositions and methods useful for modulating angiogenesis
HK09111737.6A HK1131912A1 (en) 2000-08-08 2009-12-14 Pharmaceutical compositions and methods useful for modulating angiogenesis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK12101876.3A HK1161113A1 (en) 2000-08-08 2009-12-14 Pharmaceutical compositions and methods useful for modulating angiogenesis
HK12101889.8A HK1161115A1 (en) 2000-08-08 2009-12-14 Pharmaceutical compositions and methods useful for modulating angiogenesis

Country Status (10)

Country Link
EP (4) EP2359853B1 (es)
AT (1) ATE493147T1 (es)
AU (1) AU2001280056A1 (es)
CY (3) CY1111869T1 (es)
DE (1) DE60143754D1 (es)
DK (4) DK2359853T3 (es)
ES (4) ES2437093T3 (es)
HK (3) HK1161113A1 (es)
PT (4) PT2359854E (es)
WO (1) WO2002011667A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2003225563A1 (en) * 2002-02-12 2003-09-04 Curagen Corporation Compositions and methods for treatment of osteoarthritis
FR2855968B1 (fr) * 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
JP2007526247A (ja) 2004-01-23 2007-09-13 マサチューセッツ・アイ・アンド・イア・インファーマリー リジルオキシダーゼ様１（ｌｏｘｌ１）および弾性繊維形成
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CN101835490A (zh) 2007-08-02 2010-09-15 阿雷斯托生物科学股份有限公司 Lox和loxl2抑制剂及其应用
DE102007051006A1 (de) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stabile, synergistische Mischungen
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
SG2014004816A (en) 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
RU2549684C2 (ru) 2010-02-04 2015-04-27 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
WO2001083702A2 (en) * 2000-05-03 2001-11-08 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
DK2078531T3 (da) 2012-09-10
EP2359854B1 (en) 2013-10-09
HK1161113A1 (en) 2012-08-24
EP2078531A3 (en) 2010-01-20
EP2359853A1 (en) 2011-08-24
WO2002011667A2 (en) 2002-02-14
EP2359854A1 (en) 2011-08-24
EP2359853B1 (en) 2013-11-06
EP2078531B1 (en) 2012-05-30
PT1315519E (pt) 2011-03-17
DE60143754D1 (de) 2011-02-10
AU2001280056A1 (en) 2002-02-18
DK2359853T3 (da) 2013-12-09
ES2437093T3 (es) 2014-01-08
CY1114734T1 (el) 2016-12-14
EP2078531A2 (en) 2009-07-15
EP1315519A2 (en) 2003-06-04
DK1315519T3 (da) 2011-04-11
ES2358581T3 (es) 2011-05-12
DK2359854T3 (da) 2013-11-04
PT2078531E (pt) 2012-08-06
EP1315519B1 (en) 2010-12-29
ES2387329T3 (es) 2012-09-20
PT2359853E (pt) 2013-12-26
CY1111869T1 (el) 2015-11-04
EP1315519A4 (en) 2005-09-14
CY1113142T1 (el) 2016-04-13
ATE493147T1 (de) 2011-01-15
ES2440932T3 (es) 2014-01-31
WO2002011667A3 (en) 2003-03-27
HK1161115A1 (en) 2012-08-24
PT2359854E (pt) 2013-11-22

Similar Documents

Publication Publication Date Title
HK1161115A1 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis
CY1115583T1 (el) Σκευασμα που περιλαμβανει μεταλλαγμα/τα της λυσοσωμικης αλφα-γαλακτοσιδασης α για τη θεραπευτικη αντιμετωπιση της νοσου fabry
AU7213698A (en) The use of fumaric acid derivatives
HU9701059D0 (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
GR3032673T3 (en) Use of an effective quantitiy of active substances for the treatment of mixed skin.
EP0527801A4 (en) Thiophene sulfonamides useful as carbonic anydrase inhibitors
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
ES2090244T3 (es) Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
DE59509395D1 (de) Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
ATE231388T1 (de) Lang wirksames mittel zur rektalen verabreichung
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
AU6932691A (en) Administration method of antithrombin
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
ATE297749T1 (de) Verwendung von peptidischen bradykinin- antagonisten zur herstellung von arzneimitteln
FR2772616B1 (fr) Composition depigmentante
IL132504A0 (en) Methods for reducing fibrinogen
EP0721781A3 (en) Reduction of adipose tissue by using collagenase
GEU199424Y (en) Method for Dreinage of Liver Echinococcus cyst Remnant Cavity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190805